Today: 10 June 2026
Lam Research stock drops after insider sale filing; what LRCX investors watch next
10 February 2026
1 min read

Lam Research stock drops after insider sale filing; what LRCX investors watch next

NEW YORK, Feb 10, 2026, 11:56 EST — Regular session

Lam Research (LRCX.O) shares slipped 2.6% to $223.23 in late morning action Tuesday, deepening the chip-equipment maker’s retreat from the previous close. The stock moved in a $220.40-to-$230.60 band, as semiconductor ETFs also ticked lower.

The drop comes while investors parse new sentiment signals tied to U.S. semiconductor equipment stocks—those names have been swinging hard as factory spending bets shift. When positions are packed in, even minor analyst tweaks or insider trades can sting a little more.

Lam director Eric Brandt offloaded 35,000 shares on Feb. 6, according to a Form 4 insider filing. The transactions were split between $220.95 and $230.00 per share. Following those trades, Brandt’s stake stood at 253,705 shares.

Bernstein bumped up its price target on Lam, raising it to $285 from $275, while sticking with its outperform call, MT Newswires reported.

Lam’s last quarter wrapped up with $5.34 billion in revenue and non-GAAP earnings of $1.27 per share, reported Jan. 28. Those non-GAAP numbers leave out items like one-offs. For the March period, the company guided to $5.7 billion in sales, give or take $300 million, and expects non-GAAP EPS at $1.35, plus or minus a dime. “Lam delivered another strong quarter to cap a record year,” CEO Tim Archer said at the time. Lam Research Newsroom

Insider sales are often set up in advance, so they’re not always a perfect read on how a company’s actually performing. Chip-tool stocks? They can flip direction quickly—sometimes all it takes is one surprising inflation reading, or maybe a customer saying something cautious. By lunchtime, that can drown out everything else.

Next up, traders will be eyeing Applied Materials (AMAT.O), with fiscal first-quarter numbers set for release on Feb. 12. The earnings call hits at 4:30 p.m. ET. Semiconductor equipment names tend to move together, as order books and China-related exposure get parsed by investors.

Macro factors are also in play. The Bureau of Labor Statistics has the U.S. Employment Situation report for January lined up for Feb. 11 at 8:30 a.m. ET, with the January CPI set to follow on Feb. 13, same time.

Lam’s in the spotlight as Applied Materials reports Thursday, with Friday’s CPI looming. Investors are watching to see if chip-gear valuations stay squeezed, or if there’s finally an opening for buyers to move in.

Stock Market Today

  • Kalshi Co-Founder Predicts Prediction Markets Will Surpass Stock Exchanges
    June 10, 2026, 5:42 PM EDT. Kalshi co-founder and COO Luana Lopes Lara stated at Web Summit Rio on June 10, 2026, that prediction markets could become larger than traditional stock exchanges despite potential losses for participants. Prediction markets involve trading contracts based on event outcomes, differing from equity markets by focusing on future predictions rather than ownership. Lopes Lara highlighted Kalshi's readiness to collaborate closely with regulatory bodies to ensure compliance and foster growth. This outlook underscores the growing interest in alternative trading platforms challenging conventional financial markets.

Latest articles

YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Snap Inc. Targets Health Ad Dollars With New Snapchat Study as Pressure Builds

Snap Shares Drop Again With Tech Names Under Pressure

10 June 2026
Snap Inc. shares slid 4% to $5.38, extending a three-day losing streak and deepening doubts about its turnaround despite improved cash flow and cost cuts, as investors await CEO Evan Spiegel’s June 16 AWE keynote and weigh weak ad growth, falling eCPMs, and ongoing macro and regulatory risks.
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

10 June 2026
Outlook Therapeutics soared 26% to $0.89 on heavy volume as investors zeroed in on the FDA’s 60-day review window for Lytenava after a successful appeal, but risks remain with the stock still under $1, looming Nasdaq compliance deadlines, and warnings of possible dilution and going-concern doubts if FDA approval or favorable labeling isn’t secured soon.
Silver price jumps again as dollar slips — here’s what traders watch next
Previous Story

Silver price jumps again as dollar slips — here’s what traders watch next

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view
Next Story

QVC Group stock (QVCGA) plunges on creditor-talks report as bankruptcy risk comes into view

Go toTop